Mobile Site ›

Clopidogrel Platelet Function Tests

Caveats and Controversies



Subscribe

Receive notification when new Hot Topics are published:

Warning: Diminished Effectiveness In Poor Metabolizers

Slide 33

December 2011

The warning from the FDA stated that clopidogrel metabolism depends primarily on the enzyme CYP2C19. Patients who were poor metabolizers treated with clopidogrel at the usual dose were at higher risk for a cardiovascular event after acute coronary syndrome or percutaneous coronary intervention than patients with normal metabolism. There is genetic testing available to determine the patient's CYP2C19 genotype and aid in guiding therapy. Alternative dosing or drug treatment should be considered in patients identified as poor metabolizers.

Diminished Effectiveness In Poor Metabolizers

 


Jump to section:


Key